DOCSLIB.ORG

AVT Figure Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AVT Figure Template Jensen 5/2/08 14:53 Page 31 Antiviral Therapy 13 Suppl 1:31–36 Review Future directions in therapy for chronic hepatitis C Donald M Jensen1* and Antonio Ascione2 1Center for Liver Diseases, University of Chicago Hospitals, Chicago, IL, USA 2Liver Unit, Cardarelli Hospital, Naples, Italy *Corresponding author: E-mail: [email protected] The development of new antiviral therapies in the pegylated interferon, particularly in the presence of treatment of hepatitis C virus (HCV) is reviewed, ribavirin, has resulted in significant improvements in including a discussion of the potential advances that antiviral activity. Preliminary studies have confirmed this treatment will bring. Data from new molecules in that the new molecules are well tolerated and further Phase I and II clinical trials, specifically polymerase and clinical studies are underway to evaluate their efficacy. protease inhibitors, will be discussed. The potential for Nevertheless, because of its critical role at all stages of resistance has been reported when these have been used therapy, pegylated interferon is likely to remain the as monotherapy. However, their use in combination with cornerstone of HCV therapy. Introduction The combination of pegylated interferon (PEG-IFN) comprises IFN-α2b linked to human albumin. In a plus ribavirin is the current standard of care for randomized, multicentre, Phase II trial, the drug was patients with chronic hepatitis C and is likely to remain combined with ribavirin and was administered at doses the backbone of treatment for this condition for the of 1,000 or 1,200 mg/day at 2- and 4-week intervals foreseeable future [1,2]. Optimizing therapy with the for a total of 48 weeks. There was no significant standard of care is an effective strategy that will improvement in sustained virological response (SVR) improve outcomes over the next few years (see articles rates in patients treated with alb-IFN-α2b plus by Lee and Ferenci and by Berg and Carosi in this ribavirin compared with a control group treated with supplement [3,4]). The development of novel agents the combination of PEG-IFN-α2a (40 kDa; Pegasys®; with enhanced efficacy and/or better tolerability may Roche, Basel, Switzerland) plus ribavirin (Copegus®; lead to considerable improvements in outcomes over the Roche; 51–59% versus 58%) [6]. long term. Therapeutic classes with clinical potential Only after the intent-to-treat population was limited within the next 5 years are shown in Table 1. to those patients with >75 kg bodyweight and >80% adherence could superiority of the alb-IFN-α2b treat- Modified IFNs ment arms over PEG-IFN-α2a be demonstrated. The rate of discontinuations because of adverse events was An avenue that is being actively pursued is enhancing consistently higher in patients treated at 2- and the activity of IFN. One approach is to produce novel 4-week intervals with alb-IFN-α2b (9–18%) than α α IFN- analogues with improved antiviral and Th1- with PEG-IFN- 2a (6%) [6]. inducing activity through ‘gene shuffling’. This approach has led to the development of interferon Specifically targeted antiviral therapy for compounds with more than 10-fold greater antiviral chronic hepatitis C activity than IFN alfacon-1 [5]. Clinical trials in patients with chronic hepatitis C are awaited with great interest. A number of compounds with direct activity against Another ongoing programme is dedicated to hepatitis C virus (HCV) are under clinical develop- producing an IFN with a longer elimination half-life ment. The most advanced compounds are those that than the commercially available PEG-IFNs. target HCV polymerase or HCV protease enzymes. Alb-IFN-α2b (Albuferon®; Human Genome Sciences, Rather than attempting to replace the existing standard Rockville, MD, USA) is a long-acting preparation that of care, the best way to make use of these compounds, © 2008 International Medical Press 1359-6535 31 Jensen 5/2/08 14:53 Page 32 DM Jensen & A Ascione Table 1. Potential therapies for chronic hepatitis C in active clinical development Potential therapy Specific examples Stage of development Long-acting interferon preparations Alb-IFN-α2b Phase III Direct-acting antiviral compounds that target HCV Protease inhibitors (for example, telaprevir) Phase II Polymerase inhibitors (for example, R1626) Phase II Ribavirin analogues Taribavirin Phase II Therapeutic vaccines IC41 Phase II GI-5005 Phase IB Alb-IFN-α2a, albumin-interferon-α2a; HCV, hepatitis C virus. at least in the near future, is to use them in combination HCV protease inhibitors with PEG-IFN and ribavirin. The main reason for this is to reduce the risk of resistance. Resistance has been The NS3-4A serine protease of HCV is a multifunctional reported with both polymerase and protease protein that is essential for post-translational processing inhibitors when administered as monotherapy [2,7,8]. of viral proteins. This protein is the target of several The ultimate goal is to significantly improve SVR development programmes. Development of BILN 2061 rates and/or enhance patient convenience by (Boehringer Ingelheim, Ingelheim, Germany), the first of decreasing the total duration of treatment required to these agents to show promising antiviral activity and the eradicate the virus. The greatest need is in patients first to enter the clinic, was discontinued because of infected with HCV genotype 1, in whom SVR rates cardiotoxicity in animals [9]. When used alone, are lowest, and in those who have failed previous protease inhibitors promote the emergence of resistant IFN-based therapy because the chance of a cure is variants [10,11]; therefore, all ongoing development <20% with existing therapy. programmes are evaluating protease inhibitors in Resistant variants of the virus have been detected combination with PEG-IFN. in patients treated with protease inhibitors and poly- merase inhibitors. As monotherapy, this resistance Telaprevir would likely develop before viral eradication could Telaprevir (VX-950; Vertex, Cambridge, MA, USA) is in be accomplished. It is unlikely that cross-resistance Phase II of development and is presently the best charac- will occur between agents of different classes because terized protease inhibitor and the furthest down the road of their distinct therapeutic targets, but, at present, to market. An understanding of the efficacy, toxicity and few data are available on which to base combination resistance profile of the drug is emerging. Mutations therapy. Measures to delay or prevent the emergence were detected at four positions in the NS3 serine of resistant HCV variants are mandatory for protease gene in HCV RNA isolated from the serum of ensuring the clinical usefulness of experimental ther- patients after 14 days of monotherapy with oral apies [8]. Potential strategies include administering telaprevir (750 mg every 8 h or 1,250 mg every 12 h). newer antiviral agents with low barriers to genetic One variant conferred high-level resistance with a 781- resistance against the background of the current stan- fold increase in 50% inhibitory concentration (IC50) dard of care (that is, PEG-IFN plus ribavirin) or in compared with wild-type HCV [8]. After withdrawal of combinations that do not demonstrate cross-resistance. the drug, wild-type virus re-emerged and became The former strategy is currently viable, whereas the predominant; however, variants with low-level resistance latter will remain theoretical until the efficacy, safety to telaprevir (four- to sevenfold increase in IC50) were and resistance profiles of several agents have been still detectable 3–7 months after treatment [8]. fully characterized. Rapid and sustained reductions in serum HCV The ideal PEG-IFN for use in combination with the RNA levels were obtained in patients with HCV newer agents should have a rapid onset of action and genotype 1 infection given telaprevir three times show consistent activity throughout the dosing daily in combination with PEG-IFN-α2a 180 μg once interval in order to minimize the likelihood of resis- weekly. After 14 days of treatment, median reduc- tance. The agents used in combination with new tions in HCV RNA were greater in patients treated α antivirals have included both PEG-IFN- 2a and with the combination (5.5 log10 IU/ml) than α α PEG-IFN- 2b. The more sustained serum levels of monotherapy with either PEG-IFN- 2a (1.1 log10 α PEG-IFN- 2a are a distinct advantage in achieving IU/ml) or telaprevir (4.0 log10 IU/ml) [12]. steady viral load reduction without fluctuations, Telaprevir has now advanced to Phase II clinical which can give rise to viral rebound. trials in which it is being studied in treatment-naive and 32 © 2008 International Medical Press Jensen 5/2/08 14:53 Page 33 Future directions in therapy for chronic hepatitis C treatment-experienced patients infected with HCV SVR rates in patients treated with telaprevir and that genotype 1. In the Phase II PROVE-1 trial in treatment- SVR rates of 60–65% may be possible with a 24-week naive patients, telaprevir 750 mg every 8 h has been triple-therapy regimen in genotype 1 patients. combined with a therapeutic backbone of PEG-IFN-α2a (40 kDa) 180 μg/week plus ribavirin 1,000 or 1,200 Boceprevir mg/day [13]. The study involved four treatment groups, Boceprevir (SCH 503034; Schering-Plough three of which were treated with the triple-therapy Corporation, Kenilworth, NJ, USA) is less potent than regimen for 12 weeks followed by 0, 12, or 36 weeks of telaprevir. Mean reductions in serum HCV RNA were α PEG-IFN- 2a plus ribavirin combination therapy. The 1.08 log10 and 1.61 log10 after 1 week of treatment control group was treated with the standard of care: with boceprevir 200 mg and 400 mg three times daily, 48 weeks of treatment with PEG-IFN-α2a plus ribavirin. respectively, in patients with HCV genotype 1 infec- An interim analysis of data collected at the end of tion who had not responded to previous IFN-based the triple-therapy phase of the trial (week 12) showed therapy [17].
Load more

Recommended publications
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • Polymerase Inhibitors
    New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14th - 15th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B NS5A NS3 Bifunctional NS5B RNA-dependent protease / helicase RNA polymerase Antiviral Activity of DAAs Vary Among and Within Classes 3-14 day monotherapy in genotype 1 patients NS3 protease inhibitors NS5A inhibitors non-nucleoside inhibitors nucleos/tide inhibitors Median or Mean HCV RNA Decline (log IU/mL) Median or Mean HCV RNA BCP, boceprevir; TVP, telaprevir. Sarrazin C, Zeuzem S. Gastroenterology. 2010;138:447-62. Characteristics of DAAs and HTAs Efficacy Genotype Barrier to independency resistance NS3/4A (protease inhibitors) +++ ++ + - ++ NS5A +++ + - ++ + - ++ NS5B (nucleosides) + - +++ +++ +++ NS5B (non-nucleosides) + - ++ + + Cyclophilin Inhibitors ++ +++ +++ Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > Nucleosidic polymerase inhibitors • RG-7128 (Mericitabine): moderate efficacy, safe • GS-7977 (Sofosbuvir): high efficacy, safe • Alios-2200 = VX135: high efficacy, early phase 2 • NM-283 (Valopicitabine): low efficacy, GI toxicity > • R-1626: moderate efficacy, lymphopenia > • INX-189 = BMS-986094: high efficacy, cardiac tox. > • IDX-184: moderate efficacy, on hold • PSI-938: high efficacy, hepatotoxicity > PROPEL study: Efficacy and safety of MCB + PR in G1/4 treatment-naive patients . Mericitabine nucleoside analog MCB 500 mg 12 wk (RVR-guided) polymerase inhibitor 100 MCB 1000 mg 8 wk (RVR-guided) MCB 1000 mg 12 wk (RVR-guided) .
    [Show full text]
  • Hepatitis C Virus Treatment in the Real World: Optimising Treatment and Access to Therapies
    Recent advances in clinical practice Hepatitis C virus treatment in the real world: optimising treatment and access to therapies 1 2 3 4 Editor’s choice Fabien Zoulim, T Jake Liang, Alexander L Gerbes, Alessio Aghemo, Scan to access more 5,6,7,8 9 10 11 free content Sylvie Deuffic-Burban, Geoffrey Dusheiko, Michael W Fried, Stanislas Pol, Jürgen Kurt Rockstroh,12 Norah A Terrault,13 Stefan Wiktor14 For numbered affiliations see ABSTRACT treatments—how can we improve access to diagno- end of article. Chronic HCV infections represent a major worldwide sis and treatment for those patients who need them Correspondence to public health problem and are responsible for a large most? Professor Fabien Zoulim, proportion of liver related deaths, mostly because of Gut brought together some of the leading global Université Lyon 1, Cancer HCV-associated hepatocellular carcinoma and cirrhosis. experts in HCV to discuss these questions and Research Center of Lyon The treatment of HCV has undergone a rapid and point a way forward. The round table, held during (CRCL), INSERM U1052, spectacular revolution. In the past 5 years, the launch of the European Association for the Study of the Hospices Civils de Lyon 69003, ’ France; direct acting antiviral drugs has seen sustained Liver s International Liver Congress 2015, brought [email protected] virological response rates reach 90% and above for clarity to some of these issues and looked into the many patient groups. The new treatments are effective, future pipeline of HCV treatment. This article aims Received 21 July 2015 well tolerated, allow for shorter treatment regimens and to summarise that shared knowledge.
    [Show full text]
  • Idenix Pharmaceuticals: Building a Leading Antiviral Franchise
    Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi, Ph.D. Chairman and CEO January 2005 Updated: 12/12/04 Safe Harbor This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processes and commercialization activities. These forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These risks and uncertainties are detailed in our filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation and, except as required by law, we undertake no obligation to update such statements. 2 2 Idenix – Building a Leading Antiviral Franchise MissionMission Founded in 1998 to discover, develop and commercialize innovative antiviral drugs addressing unmet medical needs in large and growing markets ProductsProducts 3 clinical stage drugs AllianceAlliance Novartis global alliance enhances commercial and financial position GlobalGlobal 150 employees at 3 locations in U.S. StructureStructure and Europe FinancialFinancial Strong balance sheet PositionPosition 3 3 Idenix Platform and Drug Discovery Capabilities A Research Engine Leading to Innovative Small Molecule Antivirals Well-definedWell-defined targets:targets: The Hepatitis B Virus Replication Cycle viralviral polymerasespolymerases DrugDrug discoverydiscovery
    [Show full text]
  • Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry
    Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2017 Clinical/Antimicrobial Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: [email protected] https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) November 2017 Clinical/Antimicrobial TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 III. DEVELOPMENT PROGRAM ....................................................................................... 3 A. General Drug Development Considerations ................................................................................ 3 1. Nonclinical Virology Development Considerations .......................................................................
    [Show full text]
  • Potential Use of Antiviral Agents in Polio Eradication Armando M
    Potential Use of Antiviral Agents in Polio Eradication Armando M. De Palma,* Gerhard Pürstinger,† Eva Wimmer,† Amy K. Patick,‡ Koen Andries,§ Bart Rombaut,¶ Erik De Clercq,* and Johan Neyts* In 1988, the World Health Assembly launched the poliomyelitis, chronic infection of immunodefi cient per- Global Polio Eradication Initiative, which aimed to use large- sons, and the reestablishment of poliomyelitis through scale vaccination with the oral vaccine to eradicate polio circulating vaccine-derived PV (5). A panel was convened worldwide by the year 2000. Although important progress by the National Research Council to evaluate the poten- has been made, polio remains endemic in several countries. tial for an antiviral drug as one of the tools to minimize Also, the current control measures will likely be inadequate poliomyelitis risk after OPV cessation. The conclusion of to deal with problems that may arise in the postpolio era. A panel convoked by the National Research Council con- the panel was that it would be appropriate, and possibly cluded that the use of antiviral drugs may be essential in the essential, to develop antiviral drugs for PV infection, as polio eradication strategy. We here report on a compara- an additional tool to address the problems that might arise tive study of the antipoliovirus activity of a selection of mol- in the “postpolio” era (6). Antiviral agents do not confer ecules that have previously been reported to be inhibitors immunity but could be used prophylactically as well as of picornavirus replication and discuss their potential use, therapeutically. They could protect inactivated polio vac- alone or in combination, for the treatment or prophylaxis of cine (IPV) recipients from PV infection, limit spread until poliovirus infection.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Proprotein Convertases and Serine Protease Inhibitors: Developing Novel Indirect-Acting Antiviral Strategies Against Hepatitis C Virus
    PROPROTEIN CONVERTASES AND SERINE PROTEASE INHIBITORS: DEVELOPING NOVEL INDIRECT-ACTING ANTIVIRAL STRATEGIES AGAINST HEPATITIS C VIRUS by Andrea D. Olmstead B.Sc., The University of Saskatchewan, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE STUDIES (Microbiology and Immunology) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) December 2011 © Andrea D. Olmstead, 2011 Abstract Hepatitis C virus (HCV) utilizes host lipids for every stage of its lifecycle. HCV hijacks host lipid droplets (LDs) to coordinate assembly through the host lipoprotein assembly pathway; this facilitates uptake into hepatocytes through the low density lipoprotein receptor (LDLR). Induction of host lipid metabolism by HCV supports chronic infection and leads to steatosis, exacerbating liver dysfunction in infected patients. One pathway activated by HCV is the sterol regulatory element binding protein (SREBP) pathway which controls lipid metabolism gene expression. To activate genes in the nucleus, SREBPs must first be cleaved by host subtilisin kexin isozyme-1/site-1 protease (SKI-1/S1P). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is one SREBP-regulated protein that post-translationally decreases LDLR expression in the liver. The overall aim of this thesis was to determine the potential application of these two important regulators of host lipid homeostasis, PCSK9 and SKI-1/S1P, as targets for inhibiting HCV infection. The first hypothesis tested was that inhibiting SKI-1/S1P would block HCV hijacking of the SREBP pathway and limit sequestration of host lipids by HCV, blocking virus propagation. To inhibit SKI-1/S1P function, an engineered serine protease inhibitor (serpin) and a small molecule inhibitor were employed.
    [Show full text]
  • Hepatitis C Antiviral Compositions Comprising 5
    (19) TZZ __T (11) EP 2 194 976 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/155 (2006.01) A61K 31/167 (2006.01) 09.12.2015 Bulletin 2015/50 A61K 31/18 (2006.01) A61K 31/341 (2006.01) A61K 31/36 (2006.01) A61K 31/381 (2006.01) (2006.01) (2006.01) (21) Application number: 08782880.2 A61K 31/415 A61K 31/435 A61P 31/14 (2006.01) A61K 31/7064 (2006.01) A61K 31/7068 (2006.01) A61K 45/06 (2006.01) (22) Date of filing: 04.08.2008 A61K 31/7056 (2006.01) A61K 38/21 (2006.01) (86) International application number: PCT/AU2008/001130 (87) International publication number: WO 2009/018609 (12.02.2009 Gazette 2009/07) (54) Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2’-C-methyladenosine or 2’-C-methylcytidine Antivirale hepatitis c-zusammensetzungen mit 5-(1-Methylpyrazol-4-yl)2-Naphthoylguanidine und 2’- C-methyladenosine oder 2’-C-methylcytidine Compositions antivirales pour traiter l’hépatite C à base de 5-(1- methylpyrazol-4-yl)2- naphthoylguanidineet de la 2’-C-methyladenosine ou du 2’-C-methylcytidine (84) Designated Contracting States: (74) Representative: Schlich, George et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Schlich HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT 9 St Catherine’s Road RO SE SI SK TR Littlehampton, West Sussex BN17 5HS (GB) (30) Priority: 03.08.2007 AU 2007904154 P (56) References cited: WO-A1-2006/135978 WO-A2-2004/112687 (43) Date of publication of application: 16.06.2010 Bulletin 2010/24 • UWE KOCH AND FRANK NARJES: "Recent Progress in the Development of Inhibitors of the (60) Divisional application: Hepatitis C Virus RNA-Dependent RNA 13178966.1 / 2 659 885 Polymerase", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS (73) Proprietor: Biotron Limited LTD, NETHERLANDS, vol.
    [Show full text]
  • Repurposing of FDA Approved Drugs
    Antiviral Drugs (In Phase IV) ABACAVIR GEMCITABINE ABACAVIR SULFATE GEMCITABINE HYDROCHLORIDE ACYCLOVIR GLECAPREVIR ACYCLOVIR SODIUM GRAZOPREVIR ADEFOVIR DIPIVOXIL IDOXURIDINE AMANTADINE IMIQUIMOD AMANTADINE HYDROCHLORIDE INDINAVIR AMPRENAVIR INDINAVIR SULFATE ATAZANAVIR LAMIVUDINE ATAZANAVIR SULFATE LEDIPASVIR BALOXAVIR MARBOXIL LETERMOVIR BICTEGRAVIR LOPINAVIR BICTEGRAVIR SODIUM MARAVIROC BOCEPREVIR MEMANTINE CAPECITABINE MEMANTINE HYDROCHLORIDE CARBARIL NELFINAVIR CIDOFOVIR NELFINAVIR MESYLATE CYTARABINE NEVIRAPINE DACLATASVIR OMBITASVIR DACLATASVIR DIHYDROCHLORIDE OSELTAMIVIR DARUNAVIR OSELTAMIVIR PHOSPHATE DARUNAVIR ETHANOLATE PARITAPREVIR DASABUVIR PENCICLOVIR DASABUVIR SODIUM PERAMIVIR DECITABINE PERAMIVIR DELAVIRDINE PIBRENTASVIR DELAVIRDINE MESYLATE PODOFILOX DIDANOSINE RALTEGRAVIR DOCOSANOL RALTEGRAVIR POTASSIUM DOLUTEGRAVIR RIBAVIRIN DOLUTEGRAVIR SODIUM RILPIVIRINE DORAVIRINE RILPIVIRINE HYDROCHLORIDE EFAVIRENZ RIMANTADINE ELBASVIR RIMANTADINE HYDROCHLORIDE ELVITEGRAVIR RITONAVIR EMTRICITABINE SAQUINAVIR ENTECAVIR SAQUINAVIR MESYLATE ETRAVIRINE SIMEPREVIR FAMCICLOVIR SIMEPREVIR SODIUM FLOXURIDINE SOFOSBUVIR FOSAMPRENAVIR SORIVUDINE FOSAMPRENAVIR CALCIUM STAVUDINE FOSCARNET TECOVIRIMAT FOSCARNET SODIUM TELBIVUDINE GANCICLOVIR TENOFOVIR ALAFENAMIDE GANCICLOVIR SODIUM TENOFOVIR ALAFENAMIDE FUMARATE TIPRANAVIR VELPATASVIR TRIFLURIDINE VIDARABINE VALACYCLOVIR VOXILAPREVIR VALACYCLOVIR HYDROCHLORIDE ZALCITABINE VALGANCICLOVIR ZANAMIVIR VALGANCICLOVIR HYDROCHLORIDE ZIDOVUDINE Antiviral Drugs (In Phase III) ADEFOVIR LANINAMIVIR OCTANOATE
    [Show full text]
  • 1 Identification of Potent Drugs and Antiviral Agents for the Treatment Of
    1 Identification of Potent Drugs and Antiviral Agents for the Treatment of the SARS- CoV-2 Infection N.R. Jena* Discipline of Natural Sciences, Indian Institute of Information Technology, Design, and Manufacturing Dumna Airport Road, Jabalpur-482005, India *Corresponding author’s email address: [email protected] Abstract The recent outbreak of the SARS-CoV-2 infection has affected the lives and economy of more than 200 countries. The unavailability of vaccines and the virus-specific drugs has created an opportunity to repurpose existing drugs to examine their efficacy in controlling the virus activities. Here, the inhibition of the RdRp viral protein responsible for the replication of the virus in host cells is examined by evaluating the binding patterns of various approved and investigational antiviral, antibacterial, and anti-cancer drugs by using the molecular docking approach. Some of these drugs have been proposed to be effective against the SARS- Cov-2 virus infection. In an attempt to discover new antiviral agents, artificially expanded genetic alphabets (AEGIS) such as dP, dZ, dJ, dV, dX, dK, dB, dS, dP4, and dZ5 and different sequences of these nucleotides were also docked into the active site of the RdRp protein. It is found that among the various approved and investigational drugs, the Clevudine, N4-hydroxycytidine (EIDD-1931), 2'-C-methylcytidine, EIDD-2801, Uprifosbuvir, Balapiravir, Acalabrutinib, BMS-986094, Remdesivir (full drug), GS-6620, and Ceforanide would act as potent inhibitors of the RdRp protein. Similarly, among the AEGIS nucleotides, dB, dJ, dP, dK, dS, dV, and dZ are found to inhibit the RdRp protein efficiently.
    [Show full text]